Loading company…
Minwei Biotechnology develops large-molecule drugs for metabolic and cardiovascular diseases.
Minwei Biotechnology develops large-molecule biopharmaceuticals focused on metabolic diseases and their complications, cardiovascular diseases, and other areas. The company is based in Shanghai, China, and raised Series A+ funding in September 2025 from Tencent Investment and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in